| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cerebral Hemorrhage | 11 | 2022 | 325 | 3.580 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 14 | 2020 | 223 | 3.250 |
Why?
|
| Hemangioma, Cavernous | 4 | 2020 | 69 | 1.740 |
Why?
|
| Thrombolytic Therapy | 4 | 2021 | 220 | 1.690 |
Why?
|
| Tissue Plasminogen Activator | 3 | 2020 | 162 | 1.480 |
Why?
|
| Craniotomy | 3 | 2021 | 88 | 1.440 |
Why?
|
| Intracranial Hemorrhages | 5 | 2020 | 120 | 1.200 |
Why?
|
| Minimally Invasive Surgical Procedures | 5 | 2022 | 237 | 1.090 |
Why?
|
| Skull Base | 2 | 2023 | 47 | 1.040 |
Why?
|
| Fibrinolytic Agents | 3 | 2020 | 202 | 0.970 |
Why?
|
| Skull Base Neoplasms | 1 | 2023 | 11 | 0.900 |
Why?
|
| Dura Mater | 2 | 2020 | 44 | 0.890 |
Why?
|
| Headache | 1 | 2022 | 73 | 0.820 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2019 | 81 | 0.810 |
Why?
|
| Decompression, Surgical | 2 | 2020 | 87 | 0.790 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2020 | 27 | 0.740 |
Why?
|
| Spinal Cord Diseases | 1 | 2020 | 29 | 0.740 |
Why?
|
| Cerebral Veins | 1 | 2020 | 30 | 0.730 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2020 | 20 | 0.730 |
Why?
|
| Neurofibromatosis 1 | 1 | 2020 | 36 | 0.730 |
Why?
|
| Decompressive Craniectomy | 1 | 2020 | 18 | 0.730 |
Why?
|
| Intracranial Thrombosis | 1 | 2020 | 27 | 0.730 |
Why?
|
| Puerperal Disorders | 1 | 2020 | 32 | 0.730 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 98 | 0.720 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 38 | 0.720 |
Why?
|
| Anticoagulants | 2 | 2020 | 408 | 0.710 |
Why?
|
| Transcriptome | 3 | 2020 | 580 | 0.700 |
Why?
|
| Optic Chiasm | 1 | 2019 | 16 | 0.690 |
Why?
|
| Paraganglioma | 1 | 2019 | 16 | 0.680 |
Why?
|
| Sella Turcica | 1 | 2019 | 17 | 0.680 |
Why?
|
| Cranial Fossa, Posterior | 1 | 2018 | 25 | 0.670 |
Why?
|
| Cranial Fossa, Middle | 1 | 2018 | 11 | 0.660 |
Why?
|
| Pituitary Neoplasms | 1 | 2019 | 62 | 0.660 |
Why?
|
| Postoperative Hemorrhage | 1 | 2018 | 46 | 0.620 |
Why?
|
| Thrombophilia | 1 | 2017 | 22 | 0.620 |
Why?
|
| Arnold-Chiari Malformation | 1 | 2018 | 43 | 0.620 |
Why?
|
| Central Nervous System Vascular Malformations | 1 | 2017 | 32 | 0.610 |
Why?
|
| Medulla Oblongata | 1 | 2018 | 89 | 0.610 |
Why?
|
| Thromboembolism | 1 | 2017 | 119 | 0.580 |
Why?
|
| Adenoma | 1 | 2019 | 237 | 0.580 |
Why?
|
| Apoptosis Regulatory Proteins | 5 | 2019 | 199 | 0.560 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 589 | 0.530 |
Why?
|
| Biomarkers | 6 | 2020 | 1718 | 0.510 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2020 | 456 | 0.500 |
Why?
|
| Humans | 37 | 2024 | 86678 | 0.500 |
Why?
|
| Early Detection of Cancer | 1 | 2017 | 395 | 0.470 |
Why?
|
| KRIT1 Protein | 5 | 2019 | 62 | 0.460 |
Why?
|
| Adolescent | 8 | 2022 | 8984 | 0.430 |
Why?
|
| Neurosurgical Procedures | 3 | 2023 | 213 | 0.400 |
Why?
|
| Brain Neoplasms | 3 | 2020 | 763 | 0.360 |
Why?
|
| Conservative Treatment | 2 | 2020 | 20 | 0.350 |
Why?
|
| rho-Associated Kinases | 3 | 2019 | 159 | 0.340 |
Why?
|
| Female | 20 | 2024 | 44550 | 0.340 |
Why?
|
| Membrane Proteins | 4 | 2019 | 1196 | 0.330 |
Why?
|
| Middle Aged | 12 | 2024 | 25040 | 0.320 |
Why?
|
| Disease Progression | 4 | 2020 | 1532 | 0.320 |
Why?
|
| Cohort Studies | 7 | 2020 | 2768 | 0.320 |
Why?
|
| Young Adult | 7 | 2020 | 5980 | 0.300 |
Why?
|
| Male | 18 | 2024 | 40988 | 0.290 |
Why?
|
| Diagnosis, Differential | 2 | 2022 | 1566 | 0.280 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2019 | 645 | 0.270 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2020 | 3362 | 0.260 |
Why?
|
| Aged | 9 | 2024 | 18423 | 0.250 |
Why?
|
| Glioma | 2 | 2018 | 285 | 0.240 |
Why?
|
| Adult | 12 | 2024 | 25659 | 0.240 |
Why?
|
| Stroke | 2 | 2024 | 965 | 0.240 |
Why?
|
| Treatment Outcome | 6 | 2024 | 7998 | 0.240 |
Why?
|
| Child | 5 | 2022 | 6928 | 0.230 |
Why?
|
| Cranial Fossa, Anterior | 1 | 2023 | 4 | 0.230 |
Why?
|
| Vascular Endothelial Growth Factor A | 3 | 2020 | 407 | 0.230 |
Why?
|
| rhoA GTP-Binding Protein | 2 | 2020 | 83 | 0.220 |
Why?
|
| Brain | 4 | 2020 | 2216 | 0.220 |
Why?
|
| Neoplasms | 1 | 2017 | 2898 | 0.220 |
Why?
|
| Myocardium | 3 | 2010 | 529 | 0.210 |
Why?
|
| Frontal Lobe | 1 | 2023 | 130 | 0.210 |
Why?
|
| Recovery of Function | 3 | 2019 | 272 | 0.200 |
Why?
|
| Embolization, Therapeutic | 1 | 2024 | 238 | 0.200 |
Why?
|
| ADAMTS5 Protein | 1 | 2020 | 4 | 0.190 |
Why?
|
| Versicans | 1 | 2020 | 6 | 0.190 |
Why?
|
| Child, Preschool | 4 | 2020 | 3613 | 0.190 |
Why?
|
| Plasma | 1 | 2020 | 50 | 0.190 |
Why?
|
| Pilot Projects | 2 | 2020 | 840 | 0.190 |
Why?
|
| Dilatation, Pathologic | 1 | 2020 | 54 | 0.190 |
Why?
|
| Hemorrhage | 2 | 2019 | 268 | 0.190 |
Why?
|
| Ventriculostomy | 1 | 2020 | 26 | 0.180 |
Why?
|
| Intestines | 2 | 2020 | 411 | 0.180 |
Why?
|
| Endothelium, Vascular | 2 | 2020 | 435 | 0.180 |
Why?
|
| Neurotoxins | 1 | 2020 | 49 | 0.180 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2019 | 379 | 0.180 |
Why?
|
| Head Injuries, Penetrating | 1 | 2020 | 54 | 0.180 |
Why?
|
| Metagenomics | 1 | 2020 | 83 | 0.180 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2020 | 49 | 0.170 |
Why?
|
| Wounds, Gunshot | 1 | 2020 | 72 | 0.170 |
Why?
|
| DNA, Bacterial | 1 | 2020 | 236 | 0.170 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2020 | 241 | 0.170 |
Why?
|
| Protein C | 1 | 2018 | 5 | 0.170 |
Why?
|
| Thrombomodulin | 1 | 2018 | 7 | 0.170 |
Why?
|
| Signal Transduction | 6 | 2020 | 3243 | 0.170 |
Why?
|
| Computed Tomography Angiography | 1 | 2020 | 131 | 0.170 |
Why?
|
| Phosphoproteins | 2 | 2010 | 255 | 0.170 |
Why?
|
| Supratentorial Neoplasms | 1 | 2018 | 10 | 0.160 |
Why?
|
| Encephalomalacia | 1 | 2018 | 3 | 0.160 |
Why?
|
| Magnetite Nanoparticles | 1 | 2018 | 27 | 0.160 |
Why?
|
| Feces | 1 | 2020 | 319 | 0.160 |
Why?
|
| Paresthesia | 1 | 2018 | 16 | 0.160 |
Why?
|
| Dog Diseases | 1 | 2018 | 35 | 0.160 |
Why?
|
| Myosin Type II | 1 | 2018 | 50 | 0.160 |
Why?
|
| Laminectomy | 1 | 2018 | 27 | 0.160 |
Why?
|
| Cell Membrane Permeability | 1 | 2018 | 119 | 0.160 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 3642 | 0.160 |
Why?
|
| Movement Disorders | 1 | 2018 | 44 | 0.160 |
Why?
|
| Endothelial Cells | 4 | 2019 | 429 | 0.160 |
Why?
|
| Adrenergic beta-Agonists | 2 | 2009 | 72 | 0.160 |
Why?
|
| Dacarbazine | 1 | 2018 | 102 | 0.160 |
Why?
|
| Gastrointestinal Tract | 1 | 2019 | 191 | 0.150 |
Why?
|
| Neuroimaging | 1 | 2018 | 113 | 0.150 |
Why?
|
| Feasibility Studies | 1 | 2019 | 751 | 0.150 |
Why?
|
| Intestinal Mucosa | 2 | 2019 | 797 | 0.150 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 1686 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2021 | 2601 | 0.140 |
Why?
|
| Enzyme Inhibitors | 1 | 2019 | 639 | 0.140 |
Why?
|
| Aging | 1 | 2020 | 691 | 0.130 |
Why?
|
| Double-Blind Method | 1 | 2019 | 1824 | 0.130 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 2360 | 0.130 |
Why?
|
| Seizures | 1 | 2017 | 297 | 0.130 |
Why?
|
| Oncolytic Virotherapy | 1 | 2015 | 41 | 0.130 |
Why?
|
| Heart Failure | 3 | 2010 | 1204 | 0.120 |
Why?
|
| Retrospective Studies | 4 | 2024 | 8496 | 0.120 |
Why?
|
| Mice, Knockout | 5 | 2019 | 1924 | 0.120 |
Why?
|
| Apoptosis | 2 | 2018 | 1683 | 0.120 |
Why?
|
| Microfilament Proteins | 2 | 2018 | 208 | 0.120 |
Why?
|
| Infant | 1 | 2020 | 3047 | 0.120 |
Why?
|
| Mice | 8 | 2020 | 11356 | 0.120 |
Why?
|
| Cytokines | 1 | 2017 | 778 | 0.120 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2019 | 1204 | 0.110 |
Why?
|
| Hypertension | 1 | 2022 | 1142 | 0.110 |
Why?
|
| Chicago | 1 | 2017 | 1380 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1037 | 0.110 |
Why?
|
| Prospective Studies | 2 | 2019 | 4214 | 0.110 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 1621 | 0.110 |
Why?
|
| Gene Expression Profiling | 2 | 2008 | 1384 | 0.100 |
Why?
|
| Risk Factors | 2 | 2022 | 5420 | 0.100 |
Why?
|
| MAP Kinase Kinase Kinase 3 | 2 | 2020 | 12 | 0.090 |
Why?
|
| Sarcomeres | 1 | 2010 | 23 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2010 | 36 | 0.090 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2010 | 74 | 0.090 |
Why?
|
| Animals | 9 | 2020 | 26590 | 0.090 |
Why?
|
| Ventricular Remodeling | 1 | 2010 | 96 | 0.090 |
Why?
|
| Clenbuterol | 1 | 2009 | 2 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2010 | 222 | 0.090 |
Why?
|
| Neovascularization, Physiologic | 1 | 2010 | 133 | 0.090 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2009 | 23 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 4 | 2020 | 3095 | 0.080 |
Why?
|
| RNA Splicing | 1 | 2010 | 142 | 0.080 |
Why?
|
| Mice, Transgenic | 3 | 2019 | 1540 | 0.080 |
Why?
|
| Postoperative Complications | 1 | 2018 | 2207 | 0.080 |
Why?
|
| Myocytes, Cardiac | 1 | 2010 | 275 | 0.080 |
Why?
|
| Stem Cells | 1 | 2009 | 351 | 0.070 |
Why?
|
| Cell Proliferation | 2 | 2010 | 1579 | 0.070 |
Why?
|
| Cardiomyopathies | 1 | 2009 | 240 | 0.070 |
Why?
|
| Longitudinal Studies | 2 | 2020 | 1019 | 0.070 |
Why?
|
| Disease Models, Animal | 3 | 2020 | 2231 | 0.070 |
Why?
|
| Radial Artery | 1 | 2024 | 33 | 0.060 |
Why?
|
| Time Factors | 3 | 2021 | 5214 | 0.060 |
Why?
|
| Catheters | 1 | 2024 | 74 | 0.060 |
Why?
|
| Thrombectomy | 1 | 2024 | 158 | 0.050 |
Why?
|
| ADAMTS4 Protein | 1 | 2020 | 4 | 0.050 |
Why?
|
| ADAMTS1 Protein | 1 | 2020 | 6 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2021 | 172 | 0.050 |
Why?
|
| Mice, Inbred DBA | 1 | 2020 | 148 | 0.050 |
Why?
|
| Proteolysis | 1 | 2020 | 100 | 0.050 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 6513 | 0.050 |
Why?
|
| Endothelium | 1 | 2020 | 59 | 0.050 |
Why?
|
| Myosin Heavy Chains | 2 | 2010 | 88 | 0.050 |
Why?
|
| Dextran Sulfate | 1 | 2019 | 68 | 0.040 |
Why?
|
| White Matter | 1 | 2020 | 80 | 0.040 |
Why?
|
| RNA, Messenger | 3 | 2010 | 1981 | 0.040 |
Why?
|
| Migraine Disorders | 1 | 2020 | 40 | 0.040 |
Why?
|
| Permeability | 1 | 2019 | 137 | 0.040 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2019 | 88 | 0.040 |
Why?
|
| Toll-Like Receptors | 1 | 2020 | 92 | 0.040 |
Why?
|
| Heart-Assist Devices | 1 | 2006 | 731 | 0.040 |
Why?
|
| Endothelial Protein C Receptor | 1 | 2018 | 4 | 0.040 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 2019 | 36 | 0.040 |
Why?
|
| Cardiomyopathy, Dilated | 2 | 2010 | 97 | 0.040 |
Why?
|
| Epithelium | 1 | 2020 | 319 | 0.040 |
Why?
|
| Survivors | 1 | 2020 | 226 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 294 | 0.040 |
Why?
|
| Tight Junctions | 1 | 2020 | 149 | 0.040 |
Why?
|
| X-Ray Microtomography | 1 | 2019 | 80 | 0.040 |
Why?
|
| Convection | 1 | 2018 | 12 | 0.040 |
Why?
|
| Caco-2 Cells | 1 | 2018 | 123 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2019 | 155 | 0.040 |
Why?
|
| Simvastatin | 1 | 2019 | 106 | 0.040 |
Why?
|
| Hematoma | 1 | 2019 | 104 | 0.040 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2018 | 23 | 0.040 |
Why?
|
| Ligands | 1 | 2019 | 433 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 298 | 0.040 |
Why?
|
| Occludin | 1 | 2018 | 66 | 0.040 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2019 | 318 | 0.040 |
Why?
|
| Blood Coagulation | 1 | 2018 | 91 | 0.040 |
Why?
|
| Interleukin-1beta | 1 | 2018 | 78 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2019 | 326 | 0.040 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2021 | 467 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2021 | 816 | 0.040 |
Why?
|
| Disease Management | 1 | 2020 | 327 | 0.040 |
Why?
|
| Homeostasis | 1 | 2020 | 409 | 0.040 |
Why?
|
| Iron | 1 | 2018 | 164 | 0.040 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2017 | 44 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2018 | 334 | 0.040 |
Why?
|
| Chronic Pain | 1 | 2020 | 145 | 0.040 |
Why?
|
| Dogs | 1 | 2018 | 686 | 0.040 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2020 | 262 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2010 | 715 | 0.040 |
Why?
|
| Phantoms, Imaging | 1 | 2019 | 429 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2018 | 289 | 0.040 |
Why?
|
| Machine Learning | 1 | 2019 | 232 | 0.040 |
Why?
|
| Polymers | 1 | 2018 | 202 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2018 | 256 | 0.040 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 296 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2018 | 178 | 0.040 |
Why?
|
| Nanoparticles | 1 | 2018 | 157 | 0.040 |
Why?
|
| Colitis | 1 | 2019 | 239 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 2018 | 286 | 0.040 |
Why?
|
| Actin Cytoskeleton | 1 | 2018 | 192 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 1673 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 879 | 0.040 |
Why?
|
| Cerebellum | 1 | 2018 | 247 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2017 | 369 | 0.040 |
Why?
|
| Acute Disease | 1 | 2018 | 826 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2019 | 673 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2018 | 1106 | 0.030 |
Why?
|
| ROC Curve | 1 | 2018 | 752 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2019 | 669 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 378 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2018 | 973 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2018 | 1807 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2018 | 724 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 1992 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 2706 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 1464 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 1195 | 0.030 |
Why?
|
| Phenotype | 1 | 2018 | 2380 | 0.030 |
Why?
|
| Filamins | 1 | 2010 | 19 | 0.020 |
Why?
|
| Troponin I | 1 | 2010 | 27 | 0.020 |
Why?
|
| Contractile Proteins | 1 | 2010 | 54 | 0.020 |
Why?
|
| Troponin T | 1 | 2010 | 37 | 0.020 |
Why?
|
| Leukemia Inhibitory Factor | 1 | 2009 | 4 | 0.020 |
Why?
|
| Carboxypeptidases A | 1 | 2009 | 11 | 0.020 |
Why?
|
| Chemokine CCL22 | 1 | 2009 | 5 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2009 | 17 | 0.020 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2009 | 44 | 0.020 |
Why?
|
| LIM Domain Proteins | 1 | 2009 | 25 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 1 | 2009 | 73 | 0.020 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2009 | 36 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2009 | 57 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2009 | 117 | 0.020 |
Why?
|
| Ion Transport | 1 | 2008 | 81 | 0.020 |
Why?
|
| Apolipoprotein A-I | 1 | 2009 | 71 | 0.020 |
Why?
|
| Myocardial Ischemia | 1 | 2010 | 162 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2010 | 782 | 0.020 |
Why?
|
| Aortic Valve Stenosis | 1 | 2010 | 131 | 0.020 |
Why?
|
| Muscle Proteins | 1 | 2009 | 132 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2010 | 302 | 0.020 |
Why?
|
| C-Reactive Protein | 1 | 2009 | 190 | 0.020 |
Why?
|
| Exons | 1 | 2010 | 450 | 0.020 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2008 | 115 | 0.020 |
Why?
|
| Heart | 1 | 2010 | 539 | 0.020 |
Why?
|
| Mutation | 1 | 2018 | 3968 | 0.020 |
Why?
|
| DNA Damage | 1 | 2008 | 366 | 0.020 |
Why?
|
| Computational Biology | 1 | 2010 | 528 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 937 | 0.020 |
Why?
|
| Stroke Volume | 1 | 2009 | 456 | 0.020 |
Why?
|
| Gene Expression | 1 | 2010 | 1284 | 0.020 |
Why?
|
| Sex Factors | 1 | 2008 | 1055 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 2009 | 592 | 0.020 |
Why?
|
| Heart Ventricles | 1 | 2010 | 760 | 0.020 |
Why?
|
| Hypoxia | 1 | 2010 | 641 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2010 | 2819 | 0.020 |
Why?
|
| Age Factors | 1 | 2008 | 1852 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2009 | 1921 | 0.010 |
Why?
|